… factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung cancer after the …
), in favor of erlotinib. Five percent of patients discontinued erlotinib because of toxic effects. …

… Purpose: Most lung cancers with activating epidermal growth factor … effects of erlotinib 150
mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib …

… to erlotinib and its impact on survival were associated with expression by the … survival
benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer, we …

… Pemetrexed and erlotinib monotherapy have different mechanisms of action and similar
clinical effectiveness compared with docetaxel but their main advantage is mild toxicity and …

… In this study, we investigated the effect of erlotinib treatment on autophagy in 4 NSCLC cell
lines with different EGFR mutation status, in order to understand the possible mechanisms …

… Question Is the combination of erlotinib and bevacizumab superior to erlotinib alone to
treat epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer? …

… in patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau
has … tyrosine kinases show that erlotinib had little inhibitory effect. Higher concentrations of …

… and erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib.
… Effects of covariates on erlotinib clearance and correlations with adverse event severity …

… kinase inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC) …
Effect of erlotinib on mean tumor volume in the H460a NSCLC xenograft model. Mice were …

… curative effect of erlotinib on non-small-cell lung cancer with … of erlotinib in the cerebrospinal
fluid exerting a curative effect … from non-small-cell lung cancer, even when treated with the …